Skip to main content
Top
Published in: BMC Ophthalmology 1/2017

Open Access 01-12-2017 | Research article

The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat’s disease

Authors: Songfeng Li, Guangda Deng, Jinghua Liu, Yan Ma, Hai Lu

Published in: BMC Ophthalmology | Issue 1/2017

Login to get access

Abstract

Background

To examined the curative effect of vitreous injection with ranibizumab,laser coagulation and cryotherapy in treating stage 3 Coats’ disease with exudative retinal detachment.

Methods

Seventeen patients with stage 3 Coats’ disease were enrolled in the study. All eyes were treated with vitreous injection of ranibizumab as initial treatment, and subsequent treatment depended on the absorption of subretinal fluid, Including cryotherapy and laser photocoagulation. Repeat treatment for the two treatment intervals occurred in ≥1 month. The mean follow-up time was 24.12 ± 5.99 months. The main data evaluation and outcome measurements included the patient’s vision, intraocular pressure(IOP), optical coherence tomography (OCT), slit lamp examination, indirect ophthalmoscopy, color Doppler imaging (CDI) and color fundus image analysis. The following variables were compared between groups: abnormal vascular changes, subretinal fluid and exudate absorption, retinal reattachment and complications. The final follow-up results were used to determine the effectiveness of treatment.

Results

Of the 17 patients included, 88.24% were male and 11.76% were female. Visual acuity was less than 0.02 in 12 eyes before surgery and 8 eyes after surgery. Visual acuity improved in 7 eyes, accounting for 41.18% of cases, and remained unchanged in 7 eyes, accounting for 41.18% of cases. Three patients were too young to undergo the operation, accounting for 17.65% of cases. The best vision was 0.1. Patients were treated 1 to 5 times for an average of 2.82 ± 0.95 times each. There was no statistically significant difference (t = 1.580, p = 0.135) between the preoperative and postoperative intraocular pressures. However, there was a statistically significant difference between the preoperative and postoperative retinal detachment height (2- related samples Wilcoxon signed rank test with z = 3.517, p = 0.000). The results further showed that all patients had different degrees of subretinal fluid absorption, and some of the new blood vessels subsided. All patients were successfully treated with laser and cryosurgery. No ocular or systemic complications were observed during follow-up.

Conclusions

Intravitreal ranibizumab (IVR), laser coagulation and cryotherapy were effective in the treatment of Coats’ disease with exudative retinal detachment.

Trial registration number

We retrospectively registered our study, The trial registration number (TRN) is ChiCTR-ONC-17011161 and date of registration is April 16, 2017.
Literature
1.
go back to reference Coats G. Forms of retinal dysplasia with massive exudation. R Lond Ophthalmol Hosp Rep. 1908;17:440–525. Coats G. Forms of retinal dysplasia with massive exudation. R Lond Ophthalmol Hosp Rep. 1908;17:440–525.
2.
go back to reference Shields JA, Shields CL, Honavar SG. Demirci H clinical variations and complications of coats disease in 150 cases: the 2000 Sanford Gifford memorial lecture. Am J Ophthalmol. 2001;131:561–71.CrossRefPubMed Shields JA, Shields CL, Honavar SG. Demirci H clinical variations and complications of coats disease in 150 cases: the 2000 Sanford Gifford memorial lecture. Am J Ophthalmol. 2001;131:561–71.CrossRefPubMed
3.
go back to reference Zhang H. Liu ZL increased nitric oxide and vascular endothelial growth factor levels in the aqueous humor of patients with coats' disease. J Ocul Pharmacol Th. 2012;28:397–401.CrossRef Zhang H. Liu ZL increased nitric oxide and vascular endothelial growth factor levels in the aqueous humor of patients with coats' disease. J Ocul Pharmacol Th. 2012;28:397–401.CrossRef
4.
go back to reference He YG, Wang H, Zhao B, Lee J, Bahl D, McCluskey J. Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab. Graef Arch Clin Exp Ophthalmol. 2010;248:1519–21.CrossRef He YG, Wang H, Zhao B, Lee J, Bahl D, McCluskey J. Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab. Graef Arch Clin Exp Ophthalmol. 2010;248:1519–21.CrossRef
5.
go back to reference Kase S, Rao NA, Yoshikawa H, Fukuhara J, Noda K, Kanda A, et al. Expression of vascular endothelial growth factor in eyes with Coats' disease. Invest Ophth Vis Sci. 2013;54:57–62.CrossRef Kase S, Rao NA, Yoshikawa H, Fukuhara J, Noda K, Kanda A, et al. Expression of vascular endothelial growth factor in eyes with Coats' disease. Invest Ophth Vis Sci. 2013;54:57–62.CrossRef
6.
go back to reference Zhao Q, Peng XY, Chen FH, Zhang YP, Wang L. You QS, et al vascular endothelial growth factor in Coats' disease. Acta Ophthalmol. 2014;92:e225–e8.CrossRefPubMed Zhao Q, Peng XY, Chen FH, Zhang YP, Wang L. You QS, et al vascular endothelial growth factor in Coats' disease. Acta Ophthalmol. 2014;92:e225–e8.CrossRefPubMed
7.
go back to reference Shields JA, Shields CL, Honavar SG, Demirci H. Cater J classification and management of coats disease: the 2000 proctor lecture. Am J Ophthalmol. 2001;131:572–83.CrossRefPubMed Shields JA, Shields CL, Honavar SG, Demirci H. Cater J classification and management of coats disease: the 2000 proctor lecture. Am J Ophthalmol. 2001;131:572–83.CrossRefPubMed
8.
go back to reference Sun Y, Jain A. Moshfeghi DM elevated vascular endothelial growth factor levels in coats disease: rapid response to pegaptanib sodium. Graef Arch Clin Exp Ophthalmol. 2007;245:1387–8.CrossRef Sun Y, Jain A. Moshfeghi DM elevated vascular endothelial growth factor levels in coats disease: rapid response to pegaptanib sodium. Graef Arch Clin Exp Ophthalmol. 2007;245:1387–8.CrossRef
9.
go back to reference Jun JH, Kim YC, Kim KS. Resolution of severe macular edema in adult coats' disease with intravitreal triamcinolone and bevacizumab injection. Korean J Ophthalmol. 2008;22:190–3.CrossRefPubMedPubMedCentral Jun JH, Kim YC, Kim KS. Resolution of severe macular edema in adult coats' disease with intravitreal triamcinolone and bevacizumab injection. Korean J Ophthalmol. 2008;22:190–3.CrossRefPubMedPubMedCentral
10.
go back to reference Ramasubramanian A, Shields CL. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction. Brit J Ophthalmol. 2012;96:356–9.CrossRef Ramasubramanian A, Shields CL. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction. Brit J Ophthalmol. 2012;96:356–9.CrossRef
11.
go back to reference Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Brit J ophthalmol. 2008;92:213–6.CrossRef Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Brit J ophthalmol. 2008;92:213–6.CrossRef
Metadata
Title
The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat’s disease
Authors
Songfeng Li
Guangda Deng
Jinghua Liu
Yan Ma
Hai Lu
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Ophthalmology / Issue 1/2017
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/s12886-017-0469-4

Other articles of this Issue 1/2017

BMC Ophthalmology 1/2017 Go to the issue